Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part I, Item 1A) of Vanda's annual report on Form 10-K/A for the fiscal year ended December 31, 2008 (File No. 001-34186). In addition to the risks described above and in Part I, Item 1A of Vanda's annual report on Form 10-K/A, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda ma
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Mass., Dec. 21 LeMaitre Vascular,Inc. (Nasdaq: ... and,implants, yesterday acquired Biomateriali S.r.l., a privately held ... cash, the assumption,of euro 0.8 million in intercompany ... 1.5 million. The acquisition was structured as a ...
... Dec. 20 MacAndrews & Forbes Holdings Inc.,announced ... President for Life,Sciences, who also serves as Chief ... to the National Biodefense Science Board (NBSB). The,NBSB ... Secretary Mike Leavitt,on scientific, technical and other matters ...
... the Record and Provide Accurate Information to ... ... VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... announced on,November 12, 2007 that their respective Boards of Directors had ...
Cached Biology Technology:LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 2LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 3Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board 2VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... the world from dying off, deep cuts in carbon ... Carnegie,s Katharine Ricke and Ken Caldeira. They find that ... ocean chemistry conditions by the end of the century ... work will be published July 3 by Environmental ...
... A single systemic dose of special immune cells prevented ... model of kidney transplantation, according to experts at the ... available in the online version of the American ... eventual human trials of the technique. , Organ transplantation ...
... 4000 elk of the Clarks Fork herd leave crowded ... into the highlands of the Absaroka Mountains, where they ... snowmelt. It,s a short trip (40-60 kilometers) by migratory ... fences, metropolitan areas, and other human-built barriers. But it ...
Cached Biology News:Major changes needed for coral reef survival 2Dendritic cell therapy improves kidney transplant survival, Pitt team says 2Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
... Stainless Steel Staining tray 19 x 29 ... staining and blot processing.Automated staining of Coomassie ... nucleic acid analysis. Prepares blots for high ... control of protocol, solution, volume, and processing ...
Complement C1r [Human]...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... designs oligos for SYBR Green, TaqMan, LNA ... FRET assays. Highly specific primers are designed ... interpreting BLAST search results. Primer efficiency is ... by connecting to the Mfold server. Beacon ...
Biology Products: